Communications
Communications

  Présentations par L. Berthoux depuis 2010
  L. Berthoux's presentations since 2010

  1. Elfayres, L. Sika, M.P. Girard, S. Khalfi, C. Letanneur, A. Singh, G. Kobinger, L. Berthoux. 2021. Cellular platforms for the generation of SARS-CoV-2 VLPs and propagation-incompetent infectious vectors. Li Ka Shing - Gairdner symposium: zooming in on COVID-19 and other viral diseases, Virtual symposium, Canada,
  2. Désaulniers, L. Ortiz, C. Dufour, C. Claudel, M.B. Plourde, N. Mérindol, L. Berthoux. 2020. Editing of the Human TRIM5 Gene Decreases the Permissiveness of Jurkat T Lymphocytic Cells to HIV-1. Viruses 2020 – novel concepts in virology, Barcelone, Espagne.
  3. Dufour, N. Joubarne, C. Claudel, N. Merindol, M.B. Plourde, L. Berthoux. 2016. CRISPR-Cas9-mediated editing of the innate effector TRIM5α gene to confer resistance to HIV-1. 12th Meeting of the Quebec Association of Gene Therapy, Montreal, Canada.
  4. Masroori, N. Mérindol, L. Berthoux. 2016. Is PML (TRIM19) a regulator or an effector in the antiviral response? 35th annual meeting of the American Society for Virology, Blackburn, VA, USA.
  5. Berthoux, U. Jung, K. Urak, M. Veillette, Q.T. Pham, M.-E. Nepveu-Traversy, J.J. Rossi. 2015. The innate immune effector TRIM5alpha as a candidate for gene-based strategies against HIV-1. 34th annual meeting of the American Society for Virology, London, Canada.
  6. Pawlica, N. Masroori, V. Le Sage, A.J. Mouland, L. Berthoux. 2014. TRIM5α Cellular Partners for the Restriction of Incoming Lentiviruses and the Activation of Innate Immune Responses. International Union of Microbiological Societies, Montreal, Canada.
  7. -É. Nepveu-Traversy and L. Berthoux. TRIM5α determinants for the activation of innate immunity. 2014. 21st Conference on Retroviruses and Opportunistic Infections, Boston, USA.
  8. -É. Nepveu-Traversy, N. Masroori, P. Pawlica, R. Gorelick, A.J. Mouland, L. Berthoux. Cellular co-factors involved in the restriction of retroviruses by proteins of the TRIM5 family. 2013. 9th retroviral nucleocapsid and assembly meeting, Montreal, Canada.
  9. Veillette, Q.T. Pham, A. Brandariz-Nunez, V. B. Shah, C. Thibert-Lefebvre, N. Chandonnet, C. R. Aiken, F. Diaz-Griffero, L. Berthoux. Mechanism of HIV-1 Resistance to Human TRIM5alpha Mutants. 2012. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, USA.
  10. T. Pham, L. Berthoux: Mutagenic screen-based selection of TRIM5α(hu) mutants that potently restrict HIV-1. 2010. Cold Spring Harbor meeting on retroviruses.
  11. -É. Nepveu-Traversy, L. Berthoux: A possible role for sumoylation in TRIM5 proteins-mediated inhibition of retroviruses. 2010. 5th International conference on SUMO, Ubiquitin and UBL proteins, Houston, TX.

   Séminaires sur invitation depuis 2010
   Invited speaker talks since 2010

  1. 2022-04-01. Hôpital Rosemont-Maisonneuve, Université de Montréal, QC. " Interactions entre le VIH-1 et son hôte cellulaire : étude et applications".
  2. 2022-03-16. Annuel meeting of the FRQS SIDA/MI network, Montreal, QC. “Les effecteurs de l'immunité innée : importance et applications".
  3. 2019-04-10. Congrès de l'Ordre Professionnel des Technologues Médicaux du Québec, Drummondville, Québec, Canada. "Relever le défi du dépistage des maladies infectieuses émergentes".
  4. 2019-03-06. CINVESTAV-IPN, Mexico City, Mexico. "The TRIM5alpha story”.
  5. 2015-06-04. Lady Davis Institute, McGill University, Montréal, QC. "Restriction and silencing of HIV-1 by TRIM19/PML”.
  6. 2015-02-27. City of Hope, Beckman Research Institute, Duarte, CA, USA. “TRIM5alpha as both an effector and an activator of innate immunity against retroviruses”.
  7. 2012-07-12. CRCHUM, Université de Montréal. "Cytosquelette, VIH, et immunité innée antivirale".
  8. 2012-10-16. INRS – Institut Armand-Frappier. "Restriction rétrovirale par TRIM5alpha : mécanismes d'action et applications biomédicales potentielles".
  9. 2010-12-09. Lady Davis Institute, McGill University, Montréal, QC. "Building antiviral genes for HIV-1 gene therapy prospects".
  10. 2010-11-25. Université Laval. "Création de gènes antiviraux dérivés de TRIM5α(hu) optimisés pour l'inhibition du VIH-1".

  Sélection de présentations par les membres du laboratoire depuis 2010
  Selected lab members' presentations since 2010

  1. Singh, K.C.G. Dos Santos, N. Merindol, V. Fourcassie, A. Droit, H. Germain, L. Berthoux. 2021. HIV-1 and IFN-I modulate the composition of the nuclear envelope proteins. Congrès CAHR, Canada (virtuel).
  2. Singh, K.C.G. Dos Santos, N. Merindol, V. Fourcassie, A. Droit, H. Germain, L. Berthoux. 2021. HIV-1 and IFN-I modulate the composition of the nuclear envelope proteins. ASV meeting, USA (virtuel).
  3. E.H. Hammami, N. Merindol, M.B. Plourde, L. Berthoux. 2019. SUMO-3 promotes the proteasomal targeting of TRIM55 through SUMO Interaction Motifs. The ubiquitin system: biology, mechanisms and roles in disease, Cavtat, Croatie.
  4. Khalfi, N. Mérindol, M.B. Plourde, M. Germain, L. Berthoux. 2019. Effet de l’autophagie sur la stimulation de l’immunité innée par TRIM5α suite à l’infection par le VIH-1. Journées Québécoises du VIH, Montréal, Canada.
  5. Mérindol. 2019. TRIM5α induit un état antiviral en réponse au VIH-1 des contrôleurs élites. Journées Québécoises du VIH, Montréal, Canada.
  6. Désaulniers, L. Ortiz, C. Dufour, A. Claudel, M.B. Plourde, N. Merindol, L. Berthoux. 2019. CRISPR-Cas9-mediated edition of the human TRIM5gene increases the resistance of Jurkat T lymphocytic cells against HIV-1infection. Symposium de l’Association Québécoise de Thérapie Génique, Montréal, Canada.
  7. Merindol, L. Blondin-Ladrie, M. El-Far, C. Tremblay, L. Berthoux. 2018. TRIM5alpha sensing of HIV-1 counteracts transcriptional latency. The 2nd Symposium of the Canadian Society for Virology, Halifax, Canada.
  8. Merindol, M. El-Far, M. Sylla, N. Masroori, C. Dufour, J-x Li, C. Tremblay, L. Berthoux. 2017. Endogenous TRIM5alpha senses HIV-1 in elite controllers and triggers an antiviral state in infected cells. Cold Spring Harbor meeting on retroviruses, NY, USA.
  9. Merindol, M. El-Far, M. Sylla, N. Masroori, J-x Li, C. Dufour, C. Tremblay, L. Berthoux. 2017. Endogenous TRIM5alpha senses HIV-1 in elite controllers. 26th Annual Canadian Conference on HIV/AIDS Research, Montreal, Canada.
  10. Masroori, P. Cherry, N. Merindol, J-x. Li, L. Poulain, M.B. Plourde, L. Berthoux. 2017. PML/TRIM19 contributes to the antiviral state against HIV-1 in a cellular context-dependent manner. 26th Annual Canadian Conference on HIV/AIDS Research, Montreal, Canada.
  11. Masroori, L. Berthoux. PML, a potential restriction factor against lentiviruses. 2014. Canadian Conference on HIV/AIDS Research, St-John’s, Canada.
  12. Pawlica, A.J. Mouland, L. Berthoux. Involvement of microtubules and dynein complexes in HIV-1 core disassembly and in its restriction by TRIM5α. 2013. 9th retroviral nucleocapsid and assembly meeting, Montreal, Canada.
  13. Pawlica, L. Berthoux: Retroviral restriction mediated by TRIM5α protein is decreased by disrupting integrity of microtubules and dynein complex. 2012. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
  14. Pawlica, M. Malbec, L. Berthoux: Identification and characterization of cellular factors involved in TRIM5alpha-mediated restriction. 2011. Cold Spring Harbor meeting on retroviruses, NY, USA.
  15. -É. Nepveu-Traversy, L. Berthoux: A mutation affecting TRIM5alpha stability, self-ubiquitylation and restriction levels. 2011. Cold Spring Harbor meeting on retroviruses, NY, USA.
  16. Veillette, Q. T. Pham, M. B. Plourde, L. Berthoux: HIV-1 resistance to restriction by human TRIM5α mutants. 2011. Cold Spring Harbor meeting on retroviruses, NY, USA.
  17. T. Pham, A. Bouchard, L. Berthoux: Generation of human TRIM5α mutants with anti-HIV-1 activity. 2010. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA.
  18. -É. Nepveu-Traversy, L. Berthoux: A role for sumoylation in TRIM5 protein-mediated restriction? 2010. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA.